China IUCD Market Research Report Information, by type (Hormonal IUD, Copper IUD and others), by end users (Hospitals, Clinics and others) - Forecast to 2032

China IUCD Market Overview

China Iucd Market Size was valued at USD 13.05 Billion in 2023. The Global China Iucd industry is projected to grow from USD 13.74 Billion in 2024 to USD 24.31 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.45% during the forecast period (2024 - 2032). IUCD stands for Intra-Uterine Contraceptive Devices. It is a device inserted into the uterus to prevent pregnancy. The device is T-shaped made up of flexible plastic with a coating of thin copper wire. China, ICUD was the most important tool to limit the couples to have one child. One child policy of China was introduced in 1979 favored the growth of this market till 2015. But in January 2016, a new law named “Two-child policy” become effective, which was passed by standing committee of National People’s Congress in December 2016. According to census 2010, the population change in is 7.39 per year.
The market for IUCD is showing a steady rise in China because most of the women still do not want to have a second child even after the passage of second child policy. The increasing incidence of unplanned pregnancies, particularly among young females, and the rising need to control population growth are the key factors driving the intrauterine contraceptive devices market in China. Similar to oral contraceptives, IUDs offer several benefits, including reduced side effects, which is a significant motivating factor. In addition, government initiatives that are favorable would further stimulate the market.

The market for intrauterine contraceptives is expanding due to the numerous positive characteristics of these products. Government programs that emphasize the advantages of IUD use have a substantial effect on market demand. Even in developing nations, disseminating the word about these instruments is motivated solely by their necessity. The market for intrauterine contraceptive devices is expanding rapidly due to rising demand and the stimulating effect of continuous innovation.

Market expansion is anticipated to be driven by an increase in demand from women who want to voluntarily delay having children. It is anticipated that the implementation of innovative strategies by the United States government to increase access to sexual and reproductive health services and products will increase the number of individuals interested in delaying pregnancy. Government and non-government organizations have made significant advances in recent years to expand access to intrauterine contraceptive devices in an effort to reduce the number of abortions and unintended pregnancies.

To prevent unwanted pregnancies and hazardous abortions, more women must have access to and utilize contraceptives such as intrauterine devices. In addition to the high product adoption rates for preventing unintended pregnancies, it has significant implications. In the future years, the far-reaching effects of unintended pregnancies are anticipated to increase market opportunities for IUDs.

May 2023: In honor of Women's Health Month, Bayer is shining a national spotlight on the impact of the underdiscussed and underdiagnosed condition of heavy menstrual bleeding (HMB) and the fact that Mirena® (levonorgestrel-releasing intrauterine system) 52 mg is an FDA-approved IUD for the treatment of heavy periods for up to 5 years in women who choose an IUD for birth control. The company's innovations have shaped and defined the women's healthcare landscape, from the introduction of the first birth control pill in 1961 to Mirena, the most commonly prescribed IUD in the United States.

Study objectives:

• Main objective of this research is to provide information about IUCD market, types of provider services and payer services.


• To provide detailed analysis of the market structure along with forecast for the next seven years of the various segments and sub-segments of the IUCD market.


• To provide insights about factors affecting the market growth.


• To analyze the IUCD based on various factors- price analysis, supply chain analysis, porters five force analysis etc.


• To provide historical and forecast revenue of the China IUCD Market segments and sub-segments with respect to China


• To provide country level analysis of the China IUCD Market with respect to the current market size and future prospective.


• To provide country level analysis of the China IUCD Market for segments by diagnosis and by end users and its sub-segments.


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the China IUCD market. 

 China IUCD Market Key Players

• SMB Corporation Of India


• Bayer HealthCare Pharmaceuticals Inc. (US) 


• Mona Lisa (Belgium)


• Teva Women’s Health 


• DKT International (US)

China IUCD Market Segmentation

The China IUCD Market is segmented into types which include hormonal IUD, copper IUD and other types. The end users are hospitals, Clinics and others.

In October 2022, a new company plans to use a technology originally developed for use on horses to create a less painful intrauterine device. IUDs are one of the most effective birth control methods, but insertion and removal can be excruciating. 3Daughters desires to supplant T-shaped IUDs with its novel magnetic, frameless IUD. The venture raised slightly more than one million dollars to advance its mission.

Copper IUDs are the only FDA-approved, extremely effective, hormone-free, reversible contraception option for women in the United States, and their design has not changed significantly in the past 35 years, according to researchers from the University of California. The Sebela Pharmaceuticals-developed IUD under study is a low-dose model with several advantageous design features. During the first year of use, a copper IUD with a novel design was safe, effective, and well-tolerated by women, according to the findings of a phase 3 clinical trial.

China IUCD Market Regional Analysis

On the basis of regions China IUCD Market is segmented into North China, Northeast China, East China, South Central China, Southwest China and Northwest China. East China account for the largest market share. It has the highest population and largest population density. The market in China is showing steady growth due to an increase in the population in all the regions.
Intended Audience

• Healthcare IT companies


• Healthcare companies


• Contract Research Organizations (CROs)


• Research and Development (R&D) Companies


• Academic Medical Institutes and Universities

The report for IUCD of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

Attribute/Metric	Details
Market Size 2023	13.05 (USD Billion)
Market Size 2024	13.74 (USD Billion)
Market Size 2032	24.31 (USD Billion)
Compound Annual Growth Rate (CAGR)	10.45 % (2024 - 2032)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2023
Market Forecast Period	2024 - 2032
Historical Data	2019 - 2023
Geographies Covered	North China, Northeast China, East China, South Central China, Southwest China and Northwest China
Key Vendors	SMB Corporation Of India,Bayer HealthCare Pharmaceuticals Inc. (US), Mona Lisa (Belgium), Teva Women’s Health, DKT International (US)